 |
0 Diseases |  |
10 Trials |
|
10 Trials |  |
41 News |  |
| «12345678910111213...2627» |
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Evaluation of T?cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_431;
Our results suggest that past CD4 count should be considered as criteria for treatment decision choice between 2DR and 3DR in order to reduce risks of age-associated complications. Co-morbidities and complications of disease and/or treatment
- Sunlenca (lenacapavir) / Gilead
Pharmacokinetics of oral islatravir (ISL) plus lenacapavir (LEN) given once weekly in an open?label, active?controlled, phase II study of virologically suppressed people with HIV?1 () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_369;
P2
LEN 300 mg QW resulted in efficacious LEN exposures, consistent with approved subcutaneous LEN. These results are consistent with previous model-based predictions and support ISL/LEN 2/300 mg QW dosing in phase III.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Comparative effectiveness of BIC/FTC/TAF versus other ART regimens in patients with AIDS?defining conditions: virological suppression and immunological recovery at 24 and 48 weeks in the ACTUAS II study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_359;
By 48 weeks, the effectiveness of the regimens becomes comparable. BIC/FTC/TAF also achieved faster virological suppression and had lower discontinuation rates.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV?infected individuals: evidence for long?term efficacy () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_326;
BIC/FTC/TAF also achieved faster virological suppression and had lower discontinuation rates. Forty-three subjects were included in this analysis: median age 54 (34
- Tybost (cobicistat) / Gilead, Prezista (darunavir) / J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Screening characteristics of participants in an open label, multi?centre, randomized controlled trial investigating integrase inhibitor versus boosted protease inhibitor antiretroviral therapy for late presenters with advanced HIV disease (LAPTOP) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_316;
LAPTOP is a 48-week, open-label, European, multi-centre, non-inferiority, controlled trial comparing outcomes for people with advanced HIV disease randomized 1:1 to receive bictegravir (BIC) or darunavir (DRV)/cobicistat (c) co-formulated with emtricitabine (FTC)/tenofovir alafenamide (TAF)...96.5% and 97.9% were fully susceptible to BIC/FTC/TAF or DRV/c/FTC/TAF, respectively (Table 1)... Almost half of LAPTOP trial participants were diagnosed after an AIDS-defining condition was present, and over half had CD4 counts less than 50 cells/
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Global survey to evaluate engagement in care and treatment experiences of people with HIV () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_298;
The overall median 10-item HIV Treatment Satisfaction Questionnaire status version score was 54/60 (n = 328); for daily oral ART, median scores were highest among those on bictegravir/emtricitabine/tenofovir alafenamide, 57/60 (n = 51)...P163: Figure 1Open in figure viewerPowerPoint Participants were asked to rank their top three treatment features, among 13 possible responses, that would be most important in remaining on HIV treatment over the long term and their top three reasons that would be most important in switching HIV treatment. Treatment features selected by >25% of participants are shown.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness and safety analysis of B/F/TAF for rapid initiation of therapy in people with HIV () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_293;
B/F/TAF has good virological suppression rate, immunological reconstitution effect, safety and high patient treatment satisfaction. B/F/TAF could be a preferred regimen for rapid initiation of ART in PWH.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness and safety of rapid initiating with BIC/FTC/TAF regimen in advanced people with HIV: a real?world study from southwest of China (EVIDENCE study) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_290;
B/F/TAF could be a preferred regimen for rapid initiation of ART in PWH. This real-world study demonstrates that rapid initiation of ART with the BIC/FTC/TAF regimen in advanced treatment-naive HIV patients achieves favourable virological suppression and immunological responses, with well safety profile.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Same?day initiation with bictegravir/emtricitabine/tenofovir alafenamide: real?life experience from a centralized single?centre model of care for people living with HIV in Croatia () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_289;
In our real-life setting, same-day treatment with B/F/TAF was virologically successful, and no documented discontinuations of B/F/TAF were observed. B/F/TAF was an efficacious option for treatment-na
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with HIV?1 (PWH): a systematic literature review (SLR) of clinical and patient?reported outcomes (PROs) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_288;
Results of this SLR demonstrate favourable efficacy and safety for B/F/TAF rapid start, supporting current HIV treatment guideline recommendations. B/F/TAF rapid start was also associated with positive PROs including high treatment satisfaction, improved health-related quality of life and reduced anxiety.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Examining the rapid initiation of B/F/TAF strategy through a Canadian lens: an HIV transmission modelling approach () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_287;
This study suggests that rapid B/F/TAF initiation represents an advantageous therapeutic strategy to reduce HIV incidence and provide cost savings for the Canadian healthcare system. Consequently, efforts should be made country-wide to adopt this strategy as the standard of care.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Multicentre, prospective cohort study of same?day initiation of antiretroviral therapy with BIC/FTC/TAF among antiretroviral?na () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_286;
Among PWH who initiated same-day ART with BIC/FTC/TAF, including a substantial proportion of PWH with high baseline PVL, two-thirds were able to achieve PVL <50 copies/ml at week 48. No BIC/FTC/TAF-related severe AEs were observed.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health?related quality of life and economic outcomes in HIV care: a sub?study of the BIC?NOW clinical trial () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_285;
No BIC/FTC/TAF-related severe AEs were observed. BIC/FTC/TAF is an appropriate, quality-of-life enhancing and pharmacoeconomically feasible option for a rapid initiation model of care in naive people living with HIV.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Synthesising HIV clinical guidelines on characteristics, challenges and facilitators of rapid initiation of antiretroviral therapy: a rapid scoping review (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_282;
Significant challenges require targeted interventions and further research, while streamlined processes, patient support and robust healthcare systems are crucial. Variations in recommendations and emerging data highlight the need for consistent guidelines.
- bictegravir (GS-9883) / Gilead, Pifeltro (doravirine) / Merck (MSD), Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of doravirine plus tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in heavily pre?treated patients () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_277;
Prior ARV was INSTI based in 12 cases (52%), PI based in one (4%), and both INSTI and PI in 10 (43%), with additional maraviroc in three cases (13%)...Among the four subjects with persistent low-grade viraemia, two changed to long-acting cabotegravir/rilpivirine with virological success, and two maintained the combination with last available HIV RNA of 1.82 and 1.90 logs, respectively. The use of DOR plus TAF/FTC/BIC in heavily pre-treated patients was safe
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of switch to bictegravir/emtricitabine/tenofovir alafenamide fumarate following dual regimen therapy in HIV: insights from the Icona cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_275;
CD4/CD8 gain is observed as a result of achieving undetectable HIV-RNA. P143: Figure 1Open in figure viewerPowerPoint (left) Characteristics of 60 people with HIV treated with 2DR INSTI-based who started treatment with B/F/TAF; (right) slopes from fitting linear mixed models adjusted for age and sex with change at B/F/TAF switch.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
The virological efficacy of B/F/TAF in people living with HIV who experienced treatment failure: a real? world cohort (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_272;
Pre-existing NRTI-related RAMs did not have adverse impact on the effectiveness of B/F/TAF. In addition, the satisfaction and adherence both improve.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir's effect on persistent low level viraemia and immunological response. BELAIR study: a pilot prospective observational study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_270;
The results of the present study indicate that BIC/TAF/FTC could improve the immunological response of PWH and limit the dimensions of persistent LLV reducing the risk of VF and drug-resistance issues. Further studies in larger patient series are needed in order to determine this beneficial role of BIC.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real?life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with a high burden of comorbidities and a history of advanced HIV disease () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_269;
Additionally, significant reductions in total cholesterol and LDL indicate potential cardiovascular benefits. These findings support B/F/TAF as an effective and safe switch strategy for PWH in clinical practice, including those with advanced HIV disease and a high comorbidity burden, including psychiatric disorders.
- Pifeltro (doravirine) / Merck (MSD)
Salvage ART regimens based on a combination of an integrase inhibitor and doravirine in heavily antiretroviral?treated people living with HIV () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_266;
These findings support B/F/TAF as an effective and safe switch strategy for PWH in clinical practice, including those with advanced HIV disease and a high comorbidity burden, including psychiatric disorders. The aim of this study was to assess epidemiological aspects and outcomes in PLWH under salvage ART regimens based on a combination of a non-nucleoside reverse transcriptase inhibitor (DOR) and an integrase inhibitor
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_259;
BFTAF has been used in people with a broad range of NRTI mutations in our clinic of which the most common was M184I/V in isolation; smaller numbers had multiple mutations including seven with K65R. Viral suppression was maintained in 108/117 (92%) of those with NRTI mutations remaining on BFTAF and with follow up of at least 24 weeks.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness of switching to B/F/TAF in virologically suppressed people with HIV and with pre?existing resistance?associated mutations in Italy: the BIC?BARRIER Study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_253;
aFor age, gender, ethnicity, HIV subtype, year of BIC initiation, number of previous regimens failure, HIV-RNA at switch, time from last available GRT and previous gap in care. bFor ethnicity, HIV subtype, year of BIC initiation, HIV-RNA at switch, time from last available GRT and previous gap in care.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
HIV?1 viral decay in blood and semen in antiretroviral?naive adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_245;
bFor ethnicity, HIV subtype, year of BIC initiation, HIV-RNA at switch, time from last available GRT and previous gap in care. These findings suggest comparable effectiveness of DTG/3TC versus BIC/FTC/TAF in achieving viral suppression in both BP and SP and similar changes in inflammatory biomarkers in blood plasma.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_237;
Antiretroviral therapy with BIC/FTC/TAF is the most commonly used ART in our hospital, being a safe therapy that is generally maintained over time and suitable for PLWH co-infected with HBV. The main reason for discontinuation is the participant's desire to switch to intramuscular therapies.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real?world evidence of B/F/TAF in Chile: effectiveness and safety from the BIKUCH cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_236;
Our results show the high effectiveness and immune recovery over time, both in TN and TE PLHIV. This cohort reinforces a B/F/TAF as an effective and safe option for ART.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
PAIRED ? PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub?analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_232;
Avoiding side effects, minimizing long-term impact and reducing the number of medicines were key factors influencing the switch. These findings suggest that DTG/3TC may offer a valuable treatment option for PWH who seek a simplified regimen with life-time exposure to fewer drugs.
- Tivicay (dolutegravir) / ViiV Healthcare
Real?world persistence of bictegravir? versus dolutegravir?based single tablet regimens in a large urban Canadian HIV centre () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_229;
STRs containing INSTIs proved to have robust persistence with discontinuations less than 30% with a long median time to discontinuation of 402 days. BIC/FTC/TAF had a preferable portfolio of persistence over DTG-containing STR regimens overall and ABC/3TC/DTG, making it a continued important choice as an ART in first-line therapy and for switch.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Demographic and clinical characteristics of treatment na () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_226;
Following balancing on population differences, HCPs' reasons for choice varied when comparing B/F/TAF and DTG/3TC. These results warrant additional studies to understand HCP perceptions of ART and PWH key groups' needs.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness and safety of BIC/FTC/TAF for late?presenting people with HIV?1 infection (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_218;
These results warrant additional studies to understand HCP perceptions of ART and PWH key groups' needs. BIC/FTC/TAF demonstrated robust virological suppression and tolerability in late-presenting PWH.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
HIV?2 chronic infection and BIC/FTC/TAF experience in a Portuguese tertiary hospital in Lisbon () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_216;
Our results support the use of BIC/FTC/TAF as a viable option in HIV-2 infection. The majority of the patients had long-term HIV-2 infection and were treatment-experienced, yet the regimen demonstrated durability and efficacy.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Incidence of comorbidities over 18 months with BIC/FTC/TAF, DTG/ABC/3TC or DTG/3TC in real?life settings in the ANRS?CO3?AquiVIH?NA cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_214;
At month 18, we observed similar incidence rates of new diagnosis of diabetes, osteoporosis and cancer between the three strategies. We observed a trend for higher incidence of hypertension in the DTG/ABC/3TC group and of eGFR <60 ml/minute in the DTG groups than in the BIC/FTC/TAF group.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long?acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real?world study (RELATIVITY Cohort) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_212;
In a real-life setting, switching to long-acting CAB+RPV seems to be a viable option for individuals with a BMI over 30, lining up with other cohorts. Further investigation is needed.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
To describe the prevalence of virological failure and resistance patterns to long?acting cabotegravir? rilpivirine: a real?life single?centre cohort study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_211;
Background: Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) is currently used as maintenance treatment for HIV-1. In our series, at week 28, the rate of VF (two consecutive VL >50 cp/ml) was low (1.25%), all of them were with low-level viraemias (<200 copies/ml) and the resistance mutations detected may reflect APOBEC activity and should be carefully interpreted by a resistance specialist.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Persistence, safety and virological outcomes of B/F/TAF as a baseline or switch regimen in HIV?infected people living with advanced HIV disease in the real world: the BIC?CD4 study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_207;
In our series, at week 28, the rate of VF (two consecutive VL >50 cp/ml) was low (1.25%), all of them were with low-level viraemias (<200 copies/ml) and the resistance mutations detected may reflect APOBEC activity and should be carefully interpreted by a resistance specialist. B/F/TAF provided excellent levels of persistence, safety profile and adequate virologic suppression rates (VSRs) in PLWH with AHD.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real?world effectiveness in treatment?experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self?reported adherence () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_199;
B/F/TAF provided excellent levels of persistence, safety profile and adequate virologic suppression rates (VSRs) in PLWH with AHD. High levels of effectiveness (>90%) were observed across all groups following switch to B/F/TAF, including in those participants with decreasing adherence over 24M.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Four?year outcomes from the BICSTaR study: observational analysis of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment?na () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_194;
High levels of effectiveness (>90%) were observed across all groups following switch to B/F/TAF, including in those participants with decreasing adherence over 24M. In a group of BICSTaR study participants with 4 years of follow-up, B/F/TAF continued to demonstrate high levels of effectiveness and tolerability in clinical practice, with some improvements in PROs observed in TN participants.
- Sunlenca (lenacapavir) / Gilead
Long acting cabotegravir plus lenacapavir as a fully injectable maintenance antiretroviral regimen in people with HIV with adherence issues () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_189;
CAB plus LEN maintained effective viral suppression with good tolerability. It holds great promise for vulnerable PLWH struggling with oral ART adherence, particularly when RPV is not an option anymore, and merits prospective evaluation in a large, randomized trial.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Antiretroviral treatment in PLWH with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: a real?world cohort analysis () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_188;
It holds great promise for vulnerable PLWH struggling with oral ART adherence, particularly when RPV is not an option anymore, and merits prospective evaluation in a large, randomized trial. There are currently no data from European studies solely focusing on virological outcomes in treatment na
- Comparison of treatment?emergent resistance associated mutations among single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV: a systematic literature review and network meta?analysis () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_181;
In VS PWH, B/F/TAF has the highest probability of preventing TE-RAMs and tended to have the lowest risk of TE-RAMs, whereas CAB+RPV Q8W performed similar to STRs with lower barriers to resistance. Since treatment is lifelong, and resistance impacts current and future treatment options, clinicians should include the differential risk of TE-RAMs in shared-decision making discussions when switching ART in stable, suppressed individuals.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Changes in patient?reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO?DOBLE randomized clinical trial () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_178;
P4
PROMs initially improved after switching to either arm, therefore, diluting the neuropsychological symptoms relative to the pre-switch status. There were no differences between arms in changes in neuropsychological PROMs from baseline.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Similar virological outcomes and frequency of isolated viraemic events (blips, low?level viraemia and suspected virological failure) between oral and long?acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long?acting studies () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_170;
Viral blips and LLV were similarly infrequent with LA and oral ART and were not associated with CVF. Isolated SVF events were rare, with similar rates of subsequent CVF with LA and comparator oral ART.
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
HIV pre?exposure prophylaxis (PrEP) failures in a large observational cohort from Poland with expansion of A6 subtype transmissions () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_150;
Isolated SVF events were rare, with similar rates of subsequent CVF with LA and comparator oral ART. Users were started on tenofovir alafenamide/emtricitabine/bictegravir in the median of 10.5 (IQR 7
- |||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, lenacapavir pro-drug (GS?4182) / Gilead, GS-1720 / Gilead
Enrollment open: Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated (clinicaltrials.gov) - Oct 23, 2024
P2/3, N=675, Recruiting, Sponsor: Gilead Sciences
Users were started on tenofovir alafenamide/emtricitabine/bictegravir in the median of 10.5 (IQR 7 Not yet recruiting --> Recruiting
- | Journal: Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. (Pubmed Central) - Oct 22, 2024
We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Oct 21, 2024
P3, N=500, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV. Recruiting --> Active, not recruiting
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal, Adherence: B/F/TAF forgiveness to non-adherence. (Pubmed Central) - Oct 17, 2024
Given this, an elevated forgiveness plays a relevant role to further improve long-term outcomes and should be considered a fundamental characteristic of any antiretroviral regimen. B/F/TAF has been proved to have all of these characteristics.
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study. (Pubmed Central) - Oct 17, 2024
Switching to DTG/3TC was noninferior to continuing B/F/TAF among adults with virologic suppression at week 48. Drug-related AEs and withdrawals were higher in the DTG/3TC arm, which is likely consistent with the open-label nature of this switch study.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Randomised, multicentre, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bictegravir/emtricitabine/ tenofovir alafenamide in people with HIV, good virological control and neuropsychiatric comorbidities: week 24 results from the GESIDA 11920 - MIND study () - Oct 15, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_104;
In PWH with pre-existing NPCs, switching from DTG/3TC to BIC/FTC/TAF did not show short-term neuropsychiatric safety benefits. However, improvements in gastrointestinal tolerability and lipid profile may justify the switch in PWH experiencing gastrointestinal intolerance and/or dyslipidaemia.
- Sunlenca (lenacapavir) / Gilead
Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: week 48 safety, efficacy, and metabolic changes () - Oct 15, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_21;
P2
Adherence to this weekly oral dosing regimen was high. ISL+LEN has the potential to become the first weekly oral complete regimen for the treatment of HIV-1 infection.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
DRUG INDUCED LIVER INJURY: A UNUSUAL CASE OF CHOLESTATIC HEPATITIS CAUSED BY HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART) () - Oct 15, 2024 - Abstract #AASLD2024AASLD_1933;
Multiple pathogenic mechanisms are reported including direct drug toxicity, immune reconstitution, hypersensitivity reaction and mitochondrial toxicity. Liver toxicity ranges from asymptomatic mild elevation of transaminases with spontaneous resolution to liver failure and death.Current best practice involves maintaining a high level of clinical suspicion and conducting thorough hepatological investigations, guided by the international RUCAM criteria, a diagnostic algorithm for DILI.